Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 20, 2017

Primary Completion Date

January 15, 2020

Study Completion Date

January 15, 2020

Conditions
Platinum Sensitive Ovarian CancerOvarian Cancer
Interventions
BIOLOGICAL

FRα peptide plus Adjuvant (GM-CSF)

Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg

DRUG

Adjuvant (GM-CSF) Alone

Intradermal injection 125 μg GM-CSF

Trial Locations (18)

10065

Memorial Sloan Kettering Cancer Center, New York

10075

Hematology/Oncology Lenox Hill Hospital, New York

19001

Abington Memorial Hospital, Abington

27710

Duke University Medical Center, Durham

32224

Mayo Clinic Florida, Jacksonville

33140

Mt. Sinai Comprehensive Cancer Center, Miami Beach

33401

Florida Cancer Specialist, West Palm Beach

33612

Moffitt Cancer Center, Tampa

35233

UAB Gynecology Oncology, Birmingham

37203

Tennessee Oncology/Sarah Cannon Research Institute, Nashville

39202

Research Partners, Jackson

55905

Mayo Clinic Rochester, Rochester

64132

MidAmerica Division, Inc. c/o Research Medical Center, Kansas City

85054

Mayo Clinic Cancer Center, Phoenix

87102

University Of New Mexico Comprehensive Cancer Center, Albuquerque

92663

Women's Cancer Research Foundation, Newport Beach

97239

OHSU, Portland

06904

The Stamford Hospital/Bennett Cancer Center, Stamford

Sponsors
All Listed Sponsors
lead

Marker Therapeutics, Inc.

INDUSTRY

NCT02978222 - Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer | Biotech Hunter | Biotech Hunter